Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ORIC 
Oric Pharmaceuticals Inc (ORIC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: ORIC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $18.9
1 Year Target Price $18.9
| 10 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.37% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 920.36M USD | Price to earnings Ratio - | 1Y Target Price 18.9 |
Price to earnings Ratio - | 1Y Target Price 18.9 | ||
Volume (30-day avg) 12 | Beta 1.48 | 52 Weeks Range 3.90 - 14.67 | Updated Date 07/4/2025 |
52 Weeks Range 3.90 - 14.67 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.87% | Return on Equity (TTM) -48.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 719848644 | Price to Sales(TTM) - |
Enterprise Value 719848644 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 85218400 | Shares Floating 46267677 |
Shares Outstanding 85218400 | Shares Floating 46267677 | ||
Percent Insiders 7.93 | Percent Institutions 102.7 |
Upturn AI SWOT
Oric Pharmaceuticals Inc
Company Overview
History and Background
Oric Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies to overcome resistance in cancer. Founded in 2014, it went public in 2020 (ORIC). Its focus is on precision medicine approaches.
Core Business Areas
- Oncology Drug Development: Focuses on developing small-molecule therapeutics targeting mechanisms of therapeutic resistance.
Leadership and Structure
The company is led by Jacob Chacko, MD, as CEO, with a management team experienced in oncology drug development. The organizational structure is typical for a biopharmaceutical company, with R&D, clinical development, and business operations functions.
Top Products and Market Share
Key Offerings
- Lerociclib (ORIC-101): An investigational glucocorticoid receptor antagonist targeting prostate cancer and other solid tumors. Currently in clinical trials. Early clinical trial data is being assessed. Competitors include companies developing novel oncology therapies, especially those targeting similar pathways.
- ORIC-533: An investigational inhibitor of polycomb repressive complex 2 (PRC2) targeting multiple myeloma. Currently in clinical trials. Early clinical trial data is being assessed. Competitors include companies developing treatments for multiple myeloma.
- ORIC-944: An investigational EHMT inhibitor targeting prostate cancer. Currently in clinical trials. Early clinical trial data is being assessed. Competitors include companies developing treatments for prostate cancer.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and rapidly growing, driven by an aging population and advances in cancer biology. The market is competitive and highly regulated.
Positioning
Oric is positioned as a precision medicine company focused on overcoming resistance mechanisms in cancer. Its competitive advantage lies in its novel drug targets and experienced management team.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars globally. Oric is targeting specific subsets of cancer patients with resistance mechanisms, representing a significant portion of the overall TAM.
Upturn SWOT Analysis
Strengths
- Novel drug targets
- Experienced management team
- Strong preclinical data
- Focus on precision medicine
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Reliance on clinical trial success
- Limited commercial infrastructure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Acquisition by a larger company
Threats
- Clinical trial failures
- Competition from other drug developers
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- GILD
- BMY
- PFE
Competitive Landscape
Oric competes with other biotechnology and pharmaceutical companies developing oncology therapies. Its success depends on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Oric's historical growth is characterized by preclinical and early clinical development activities.
Future Projections: Future growth depends on the success of its clinical trials. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing lerociclib, ORIC-533, and ORIC-944 into later-stage clinical trials.
Summary
Oric Pharmaceuticals is an early-stage biotech company focused on developing novel cancer therapies. Its success is heavily reliant on positive clinical trial data and securing partnerships. The company faces significant risks, including clinical trial failures and competition but it is positioned well with it's pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biotechnology companies is highly speculative and involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oric Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-04-24 | President, CEO & Director Dr. Jacob M. Chacko M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 122 | Website https://www.oricpharma.com |
Full time employees 122 | Website https://www.oricpharma.com | ||
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.